ANDA 209402, held by Changzhou Pharm. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 209402 (Doxycycline Hyclate), held by Changzhou Pharm, was first approved by FDA on Oct 7, 2019, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 7, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Doxycycline HyclateEQ 100MG BASE · capsule;oral | Doxycycline Hyclate | Rx |
| Sep 24, 2026 | Supplement 5Labeling · Standard review | Approved | None posted |
| Sep 24, 2026 | Supplement 13Labeling · Standard review | Approved | None posted |
| Sep 24, 2026 | Supplement 14Labeling · Standard review | Approved | None posted |
| Oct 7, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters